Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 12/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888977 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL17090761 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL31723482 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL5502782 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL6850137 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068149 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068162 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL30216573 | 0.92 | TYMP (0.47) | TYMPTK1TK2 | |
| SCHEMBL22984025 | 0.92 | TYMP (0.54) | TYMPTK1TK2 | |
| SCHEMBL7702801 | 0.92 | TYMP (0.54) | TYMPTK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695392-A2 | TREM COMPOSITIONS AND METHODS OF USE | Flagship Pioneering Innovations VI, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695391-A1 | TREMS FOR USE IN CORRECTION OF MISSENSE MUTATIONS | Flagship Pioneering Innovations VI, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025235761-A1 | REAGENTS AND PROCESSES FOR PREPARING OLIGONUCLEOTIDES | BIOGEN MA INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250346624-A1 | POLYNUCLEOTIDE AND PRODUCING METHOD THEREOF | EISAI R&D MAN CO LTD (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025095980-A1 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-08 | — | — | WO | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092392-A1 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-01-02 | — | — | US | disclosed |
| US-12121531-B2 | TREM compositions and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| WO-1998046272-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998045314-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5801154-A | Antisense oligonucleotide modulation of multidrug resistance-associated protein | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5789573-A | OLIGOMERS WHICH HYBRIDIZE WITH ENDCAPPED TARGET RNA TRANSCRIPT | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045437-A1 | COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997030067-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997029780-A1 | METHOXYETHOXY OLIGONUCLEOTIDES FOR MODULATION OF PROTEIN KINASE C EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346624-A1 | POLYNUCLEOTIDE AND PRODUCING METHOD THEREOF | POLRMT, POLN, POLM | TYMP 19/4885TK1 252/4885TK2 107/4885 |
| US-12121531-B2 | TREM compositions and uses thereof | TRMT1, TARBP1, TRMT1L | TYMP 28/4885TK1 183/4885TK2 147/4885 |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | TYMP 28/4885TK1 183/4885TK2 147/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | TYMP 671/4885TK1 743/4885TK2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.